Vor Biopharma (NASDAQ:VOR) Shares Up 12% – Still a Buy?

Shares of Vor Biopharma Inc. (NASDAQ:VOR) rose 12% on Tuesday . The company traded as high as $19.42 and last traded at $19.5360. 634,643 shares were traded during trading, a decline of 42% from the average daily volume of 1,097,242 shares. The stock had previously closed at $17.45.

Analyst Ratings Changes

A number of brokerages have issued reports on VOR. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Finally, Wedbush upped their price objective on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Stock Performance

The business’s fifty day moving average price is $16.09 and its 200 day moving average price is $15.15.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Research analysts forecast that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG lifted its stake in shares of Vor Biopharma by 284.8% in the fourth quarter. UBS Group AG now owns 292,118 shares of the company’s stock worth $3,821,000 after acquiring an additional 216,209 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $33,275,000. NEXTBio Capital Management LP acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $13,080,000. Simplify Asset Management Inc. bought a new position in Vor Biopharma during the 1st quarter worth approximately $955,000. Finally, Findell Capital Management LLC bought a new position in Vor Biopharma during the 4th quarter worth approximately $3,021,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).